VJHemOnc is committed to improving our service to you

ICML 2019 | Cami-T in R/R cHL: analysis of clinical determinants of safety and efficacy

VJHemOnc is committed to improving our service to you

Alexandre Hirayama

Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the analysis of the clinical determinants for the safety and effiacy of camidanlumab tesirine (Cami-T; ADCT-301) for relapsed/refractory classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter